Published in Nat Immunol on May 05, 2013
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol (2013) 1.72
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science (2016) 1.39
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. Front Immunol (2013) 1.34
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood (2015) 1.27
Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv (2015) 1.25
T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog (2014) 1.19
Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05
Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun (2015) 1.00
T cell exhaustion during persistent viral infections. Virology (2015) 1.00
Pembrolizumab. J Immunother Cancer (2015) 0.99
Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J (2015) 0.96
T cell responses to cytomegalovirus. Nat Rev Immunol (2016) 0.95
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology (2015) 0.94
In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol (2013) 0.90
Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection. Proc Natl Acad Sci U S A (2013) 0.90
Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol (2015) 0.89
An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses. Oncotarget (2015) 0.89
Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis. Am J Respir Crit Care Med (2016) 0.87
Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection. PLoS One (2015) 0.85
PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment. PLoS One (2015) 0.85
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. Mucosal Immunol (2014) 0.84
The Many Unknowns Concerning the Bioenergetics of Exhaustion and Senescence during Chronic Viral Infection. Front Immunol (2014) 0.84
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology (2016) 0.83
Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology (2015) 0.83
High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J Exp Med (2016) 0.83
T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant (2015) 0.82
Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host. Cell Rep (2016) 0.82
Dynamic Changes in Chromatin Accessibility Occur in CD8(+) T Cells Responding to Viral Infection. Immunity (2016) 0.81
T cell exhaustion: a means or an end? Nat Immunol (2013) 0.81
Cellular immune responses in HIV-negative immunodeficiency with anti-interferon-γ antibodies and opportunistic intracellular microorganisms. PLoS One (2014) 0.80
Genetic and Epigenetic Regulation of PD-1 Expression. J Immunol (2016) 0.80
Protective efficacy of individual CD8+ T cell specificities in chronic viral infection. J Immunol (2015) 0.80
NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun (2016) 0.80
Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers. J Infect Dis (2015) 0.80
Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. PLoS One (2014) 0.80
Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load. AIDS (2014) 0.79
Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity. Cell Rep (2016) 0.77
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J Virol (2016) 0.76
Memory of Inflammation in Regulatory T Cells. Cell (2016) 0.76
Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. Front Immunol (2015) 0.75
A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire. Cell Rep (2016) 0.75
Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS One (2015) 0.75
Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs. Eur J Immunol (2016) 0.75
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends Mol Med (2016) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
T cell exhaustion. Nat Immunol (2011) 11.08
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med (1984) 10.66
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med (1997) 8.59
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Effector and memory CTL differentiation. Annu Rev Immunol (2007) 7.17
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med (1998) 5.78
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A (2004) 4.56
T cells and viral persistence: lessons from diverse infections. Nat Immunol (2005) 4.12
CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol (2007) 3.87
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991) 3.78
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity (2008) 3.33
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 3.23
Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A (2008) 3.14
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med (2007) 3.05
Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med (2006) 2.55
High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2009) 2.42
Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev (2010) 1.85
Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol (2011) 1.66
Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev (2010) 1.59
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection. Immunity (2011) 1.53
Involvement of both T cell receptor V alpha and V beta variable region domains and alpha chain junctional region in viral antigen recognition. Eur J Immunol (1991) 1.47
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med (2012) 1.29
V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition. J Immunol (1994) 1.21
Role of thymic output in regulating CD8 T-cell homeostasis during acute and chronic viral infection. J Virol (2005) 1.15
CD8(+) T cells in preventing HIV infection and disease. AIDS (2012) 1.12
Antigen amount dictates CD8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell. Eur J Immunol (2012) 1.00
Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. HIV Med (2011) 0.99
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer (2011) 0.99
The road not taken: memory T cell fate 'decisions'. Nat Immunol (2009) 0.98
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology. Immunity (2012) 2.21
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells. Eur J Immunol (2013) 1.45
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
The three main stumbling blocks for anticancer T cells. Trends Immunol (2012) 1.38
Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep (2013) 1.37
A constant affinity threshold for T cell tolerance. J Exp Med (2007) 1.36
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
T cell division and death are segregated by mutation of TCRbeta chain constant domains. Immunity (2004) 1.24
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. PLoS One (2011) 1.20
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J Exp Med (2012) 1.15
Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods (2006) 1.13
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res (2006) 1.11
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 1.09
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother (2003) 1.09
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol (2003) 1.07
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol (2012) 1.06
The human T cell response to melanoma antigens. Adv Immunol (2006) 1.05
Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol (2012) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol (2009) 1.01
Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer (2010) 1.01
The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets (2011) 1.00
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun (2003) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res (2003) 1.00
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 0.99
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol (2010) 0.99
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer (2011) 0.99
Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC. Proc Natl Acad Sci U S A (2003) 0.99
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A (2010) 0.99
Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. J Immunol (2009) 0.98
In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J Immunol (2007) 0.97
Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations. Cytometry (2002) 0.96
Assessing ageing of individual T lymphocytes: mission impossible? Mech Ageing Dev (2007) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol (2006) 0.94
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol (2005) 0.94
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 0.93
Progress and controversies in developing cancer vaccines. J Transl Med (2005) 0.93
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol (2012) 0.92
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol (2007) 0.92
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol (2007) 0.90
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur J Immunol (2008) 0.89
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother (2008) 0.89
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother (2006) 0.89
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res (2013) 0.89
Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer (2012) 0.88
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother (2007) 0.88
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci U S A (2004) 0.86
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother (2008) 0.86
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer (2012) 0.86
Virus-like particles induce robust human T-helper cell responses. Eur J Immunol (2011) 0.85
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother (2011) 0.84
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment. PLoS One (2011) 0.84
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J Immunol (2006) 0.84
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer (2012) 0.84
Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. Eur J Immunol (2014) 0.84
Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res (2010) 0.84
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother (2010) 0.84
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother (2007) 0.83
Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol (2006) 0.82
Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. J Immunol (2004) 0.82
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81
Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol (2006) 0.81
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. Clin Cancer Res (2006) 0.81
Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma. Int J Cancer (2010) 0.81
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immun (2008) 0.81
Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother (2012) 0.80
Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. Curr Opin Immunol (2005) 0.80
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med (2014) 0.80
A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts. J Immunol Methods (2012) 0.80
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol (2006) 0.79
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotechnol (2010) 0.79
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. PLoS One (2013) 0.78
Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine (2002) 0.78